Identification

Name
Bupropion
Accession Number
DB01156  (APRD00621)
Type
Small Molecule
Groups
Approved
Description

A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment. [PubChem]

Structure
Thumb
Synonyms
  • Amfebutamone
External IDs
34841-39-9
Product Ingredients
IngredientUNIICASInChI Key
Bupropion hydrobromideE70G3G5863905818-69-1WSTCENNATOVXKQ-UHFFFAOYSA-N
Bupropion hydrochlorideZG7E5POY8O31677-93-7HEYVINCGKDONRU-UHFFFAOYNA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Bupropion XLTablet, extended release150 mgOralActavis Pharma Company2016-05-03Not applicableCanada
Act Bupropion XLTablet, extended release300 mgOralActavis Pharma Company2016-05-03Not applicableCanada
AplenzinTablet, extended release174 mg/1OralSanofi Aventis2009-03-302017-03-31Us
AplenzinTablet, extended release174 mg/1OralValeant Pharmaceuticals North America2008-04-23Not applicableUs
AplenzinTablet, extended release348 mg/1OralSanofi Aventis2009-03-302017-03-31Us
AplenzinTablet, extended release348 mg/1OralValeant Pharmaceuticals North America2008-04-23Not applicableUs
AplenzinTablet, extended release522 mg/1OralSanofi Aventis2009-03-30Not applicableUs
AplenzinTablet, extended release522 mg/1OralValeant Pharmaceuticals North America2008-04-23Not applicableUs
Aplenzin ERTablet, extended release348 mg/1OralStat Rx USA2009-03-30Not applicableUs
Ava-bupropion SRTablet, extended release150 mgOralAvanstra Inc2011-09-192014-08-21Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudeprionTablet, extended release150 mg/1Oralbryant ranch prepack2008-05-30Not applicableUs
Budeprion SRTablet, extended release150 mg/1Oralbryant ranch prepack2004-03-23Not applicableUs
Budeprion SRTablet, extended release150 mg/1OralCardinal Health2004-03-22Not applicableUs00093 5502 01 nlmimage10 742dba1d
Budeprion SRTablet, extended release100 mg/1OralCardinal Health2004-01-28Not applicableUs00093 5501 01 nlmimage10 cf2d679b
Budeprion XLTablet, film coated, extended release150 mg/1OralStat Rx USA2006-12-14Not applicableUs10370 0101 50 nlmimage10 a03fd01e
Budeprion XL XLTablet, film coated, extended release150 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-12-14Not applicableUs
BuprobanTablet, extended release150 mg/1OralTeva2004-05-27Not applicableUs00093 5703 01 nlmimage10 7d2dbe9d
BupropionTablet, extended release150 mg/1OralSolco healthcare U.S., LLC2014-11-01Not applicableUs
BupropionTablet, extended release300 mg/1OralProficient Rx LP2014-02-15Not applicableUs
BupropionTablet, extended release300 mg/1OralBlue Point Laboratories2014-10-03Not applicableUs
International/Other Brands
Elontril / Forfivo / Prexaton / Voxra
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AppbutamoneBupropion hydrochloride + L-TyrosineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Appbutamone-DBupropion hydrochloride + L-TyrosineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
ContraveBupropion hydrochloride (90 mg/1) + Naltrexone hydrochloride (8 mg/1)Tablet, film coated, extended releaseOralTakeda2014-09-10Not applicableUs
ContraveBupropion hydrochloride (90 mg/1) + Naltrexone hydrochloride (8 mg/1)Tablet, film coated, extended releaseOralA S Medication Solutions2014-09-102017-06-20Us
Contrave Extended-ReleaseBupropion hydrochloride (90 mg/1) + Naltrexone hydrochloride (8 mg/1)Tablet, extended releaseOralOrexigen Therapeutics, Inc.2014-09-10Not applicableUs
Contrave Extended-ReleaseBupropion hydrochloride (90 mg/1) + Naltrexone hydrochloride (8 mg/1)Tablet, extended releaseOralPd Rx Pharmaceuticals, Inc.2014-10-22Not applicableUs
Contrave Extended-ReleaseBupropion hydrochloride (90 mg/1) + Naltrexone hydrochloride (8 mg/1)Tablet, extended releaseOralA S Medication Solutions2014-09-102017-06-20Us
Categories
UNII
01ZG3TPX31
CAS number
34911-55-2
Weight
Average: 239.741
Monoisotopic: 239.10769191
Chemical Formula
C13H18ClNO
InChI Key
SNPPWIUOZRMYNY-UHFFFAOYSA-N
InChI
InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
IUPAC Name
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
SMILES
CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1

Pharmacology

Indication

For the treatment of depression and as aid to smoking cessation.

Structured Indications
Pharmacodynamics

Bupropion, an antidepressant of the aminoketone class and a non-nicotine aid to smoking cessation, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Compared to classical tricyclic antidepressants, Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine, serotonin, and dopamine. In addition, Bupropion does not inhibit monoamine oxidase. Bupropion produces dose-related central nervous system (CNS) stimulant effects in animals, as evidenced by increased locomotor activity, increased rates of responding in various schedule-controlled operant behavior tasks, and, at high doses, induction of mild stereotyped behavior.

Mechanism of action

Bupropion selectively inhibits the neuronal reuptake of dopamine, norepinephrine, and serotonin; actions on dopaminergic systems are more significant than imipramine or amitriptyline whereas the blockade of norepinephrine and serotonin reuptake at the neuronal membrane is weaker for bupropion than for tricyclic antidepressants. The increase in norepinephrine may attenuate nicotine withdrawal symptoms and the increase in dopamine at neuronal sites may reduce nicotine cravings and the urge to smoke. Bupropion exhibits moderate anticholinergic effects.

TargetActionsOrganism
ASodium-dependent dopamine transporter
inhibitor
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
UNeuronal acetylcholine receptor subunit alpha-3
antagonist
Human
Absorption

For sustained release, peak plasma concentrations are achieved within 3 hours.

Volume of distribution
Not Available
Protein binding

84 %

Metabolism

Reduction of the carbonyl groupand/or hydroxylation of the tert-butyl group of bupropion.

Route of elimination

Bupropion is extensively metabolized in humans. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of metachlorobenzoic acid, which is then excreted as the major urinary metabolite. Following oral administration of 200 mg of 14C-bupropion in humans, 87% and 10% of the radioactive dose were recovered in the urine and feces, respectively. However, the fraction of the oral dose of bupropion excreted unchanged was only 0.5%, a finding consistent with the extensive metabolism of bupropion.

Half life

24 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include seizures, hallucinations, loss of consciousness, tachycardia, and cardiac arrest.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
D(2) dopamine receptor---(C;C)C Allele, homozygousEffect Directly StudiedThe presence of this genotype in DRD2 is associated with improved therapeutic response to bupropion.Details

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Bupropion.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Bupropion.Experimental
AbirateroneThe serum concentration of Bupropion can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Bupropion.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Bupropion.Approved
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Bupropion.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Bupropion.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Bupropion.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Bupropion.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Bupropion.Approved, Withdrawn
AmantadineThe risk or severity of adverse effects can be increased when Amantadine is combined with Bupropion.Approved
AmineptineThe metabolism of Amineptine can be decreased when combined with Bupropion.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Bupropion.Approved, Withdrawn
AmiodaroneThe metabolism of Bupropion can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Bupropion.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Bupropion.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Bupropion.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Bupropion.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Bupropion.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Bupropion.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bupropion.Approved, Investigational
AprepitantThe serum concentration of Bupropion can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Bupropion.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Bupropion.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Bupropion.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Bupropion.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Bupropion.Approved, Withdrawn
AtazanavirThe metabolism of Bupropion can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Bupropion.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Bupropion.Approved
AzithromycinThe metabolism of Bupropion can be decreased when combined with Azithromycin.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Bupropion.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Bupropion.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Bupropion.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Bupropion.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Bupropion.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Bupropion.Approved
BoceprevirThe metabolism of Bupropion can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Bupropion.Approved, Investigational
BosentanThe serum concentration of Bupropion can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Bupropion.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Bupropion.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupropion.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Bupropion.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Bupropion.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Bupropion.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Bupropion.Approved, Illicit, Investigational, Vet Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Bupropion.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Bupropion.Approved
CapecitabineThe metabolism of Bupropion can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Bupropion.Approved
CarbamazepineThe metabolism of Bupropion can be increased when combined with Carbamazepine.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Bupropion.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Bupropion.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Bupropion.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Bupropion.Approved, Investigational
CelecoxibThe metabolism of Bupropion can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Bupropion.Approved, Vet Approved
CeritinibThe serum concentration of Bupropion can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Bupropion.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Bupropion.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Bupropion.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Bupropion.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Bupropion.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Bupropion.Approved
CholecalciferolThe metabolism of Bupropion can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholineThe serum concentration of Choline can be increased when it is combined with Bupropion.Approved, Nutraceutical
CilostazolThe metabolism of Cilostazol can be decreased when combined with Bupropion.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Bupropion.Approved
CinacalcetThe metabolism of Bupropion can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Bupropion.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bupropion.Approved
CitalopramThe risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram.Approved
CladribineThe serum concentration of Cladribine can be increased when it is combined with Bupropion.Approved, Investigational
ClarithromycinThe metabolism of Bupropion can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bupropion can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Bupropion.Approved
ClobazamThe metabolism of Bupropion can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Bupropion.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Bupropion.Approved
ClopidogrelThe serum concentration of Bupropion can be increased when it is combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Bupropion can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Bupropion.Approved
CobicistatThe serum concentration of Bupropion can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Bupropion can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Bupropion.Approved, Illicit
ConivaptanThe serum concentration of Bupropion can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Bupropion can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Bupropion can be increased when it is combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Bupropion.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Bupropion.Approved, Investigational
CyclosporineThe metabolism of Bupropion can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Bupropion can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Bupropion.Approved, Investigational
DabrafenibThe serum concentration of Bupropion can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Bupropion.Approved
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Bupropion.Approved, Investigational
DarunavirThe serum concentration of Bupropion can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Bupropion.Approved
DasatinibThe serum concentration of Bupropion can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Bupropion.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Bupropion.Approved
DeferasiroxThe serum concentration of Bupropion can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bupropion can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Bupropion.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Bupropion.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Bupropion.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Bupropion.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Bupropion.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Bupropion.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Bupropion.Approved
DibenzepinThe metabolism of Dibenzepin can be decreased when combined with Bupropion.Experimental
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Bupropion.Approved, Illicit
DihydroergotamineThe metabolism of Bupropion can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Bupropion.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Bupropion.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Bupropion.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Bupropion.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Bupropion.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Bupropion.Approved
DosulepinThe metabolism of Dosulepin can be decreased when combined with Bupropion.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Bupropion.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Bupropion.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bupropion.Approved, Investigational
DoxycyclineThe metabolism of Bupropion can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Bupropion.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Bupropion.Approved
EfavirenzThe serum concentration of Bupropion can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Bupropion.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Bupropion.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Bupropion.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Bupropion.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Bupropion.Investigational
EnzalutamideThe serum concentration of Bupropion can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Bupropion.Approved, Investigational
EpinephrineThe serum concentration of Epinephrine can be increased when it is combined with Bupropion.Approved, Vet Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Bupropion.Approved, Investigational
ErythromycinThe metabolism of Bupropion can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Bupropion.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Bupropion.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Bupropion.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Bupropion.Approved, Illicit
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Bupropion.Approved, Investigational
EtravirineThe metabolism of Bupropion can be decreased when combined with Etravirine.Approved
FelodipineThe metabolism of Bupropion can be decreased when combined with Felodipine.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bupropion.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Bupropion.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Bupropion.Approved, Withdrawn
FloxuridineThe metabolism of Bupropion can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Bupropion can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Bupropion.Approved
FluorouracilThe metabolism of Bupropion can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Bupropion.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Bupropion.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Bupropion.Approved, Investigational
FosamprenavirThe metabolism of Bupropion can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bupropion can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Bupropion can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Bupropion.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bupropion can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Bupropion.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Bupropion.Approved, Investigational
GemfibrozilThe metabolism of Bupropion can be decreased when combined with Gemfibrozil.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Bupropion.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Bupropion.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Bupropion.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Bupropion.Approved, Vet Approved
HarmalineHarmaline may increase the hypertensive activities of Bupropion.Experimental
HistamineThe serum concentration of Histamine can be increased when it is combined with Bupropion.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Bupropion.Experimental
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Bupropion resulting in a loss in efficacy.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Bupropion.Approved, Illicit
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Bupropion.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Bupropion.Approved
IdelalisibThe serum concentration of Bupropion can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Bupropion.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Bupropion.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Bupropion.Approved
IndinavirThe metabolism of Bupropion can be decreased when combined with Indinavir.Approved
Ioflupane I-123Bupropion may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Bupropion.Approved
IprindoleThe metabolism of Iprindole can be decreased when combined with Bupropion.Experimental
IproclozideIproclozide may increase the hypertensive activities of Bupropion.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Bupropion.Withdrawn
IrbesartanThe metabolism of Bupropion can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Bupropion can be decreased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Bupropion.Approved
IsoniazidThe metabolism of Bupropion can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Bupropion can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Bupropion can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bupropion can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Bupropion.Approved
KetoconazoleThe metabolism of Bupropion can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Bupropion.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bupropion.Approved, Investigational
LapatinibThe metabolism of Bupropion can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Bupropion can be decreased when combined with Leflunomide.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Bupropion.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Bupropion.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Bupropion.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Bupropion.Approved
LobeglitazoneThe metabolism of Bupropion can be decreased when combined with Lobeglitazone.Approved
LofepramineThe metabolism of Lofepramine can be decreased when combined with Bupropion.Experimental
LomustineThe metabolism of Lomustine can be decreased when combined with Bupropion.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Bupropion.Approved
LopinavirThe serum concentration of Bupropion can be decreased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Bupropion.Approved
LorcaserinBupropion may increase the serotonergic activities of Lorcaserin.Approved
LosartanThe metabolism of Bupropion can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Bupropion can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Bupropion can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bupropion can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Bupropion can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Bupropion can be decreased when combined with Manidipine.Approved
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Bupropion.Approved
MebanazineMebanazine may increase the hypertensive activities of Bupropion.Withdrawn
MemantineThe serum concentration of Memantine can be increased when it is combined with Bupropion.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Bupropion.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Bupropion.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Bupropion.Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Bupropion.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Bupropion.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Bupropion.Approved, Illicit
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Bupropion.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Bupropion.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypertensive activities of Bupropion.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Bupropion.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Bupropion.Approved, Illicit, Withdrawn
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Bupropion.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Bupropion.Approved, Investigational
MexiletineThe metabolism of Bupropion can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Bupropion.Approved
MidostaurinThe metabolism of Bupropion can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Bupropion can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Bupropion.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Bupropion.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Bupropion.Approved
MitotaneThe serum concentration of Bupropion can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypertensive activities of Bupropion.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Bupropion.Approved, Investigational
NafamostatThe serum concentration of Nafamostat can be increased when it is combined with Bupropion.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Bupropion.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Bupropion.Approved, Investigational
NefazodoneThe metabolism of Bupropion can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bupropion can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Bupropion can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bupropion can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Bupropion.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Bupropion.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Bupropion.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Bupropion.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Bupropion.Approved
NilotinibThe metabolism of Bupropion can be decreased when combined with Nilotinib.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Bupropion.Approved, Vet Approved
NorepinephrineThe serum concentration of Norepinephrine can be increased when it is combined with Bupropion.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Bupropion.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Bupropion.Withdrawn
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Bupropion.Approved, Investigational
OlaparibThe metabolism of Bupropion can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Bupropion can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Bupropion.Approved
OpipramolThe metabolism of Opipramol can be decreased when combined with Bupropion.Investigational
OsimertinibThe serum concentration of Bupropion can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Bupropion.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Bupropion.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Bupropion.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Bupropion can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Bupropion.Approved, Investigational
PanobinostatThe serum concentration of Bupropion can be increased when it is combined with Panobinostat.Approved, Investigational
PargylinePargyline may increase the hypertensive activities of Bupropion.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Bupropion.Approved
Peginterferon alfa-2bThe serum concentration of Bupropion can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Bupropion.Approved
PentobarbitalThe metabolism of Bupropion can be increased when combined with Pentobarbital.Approved, Vet Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Bupropion.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Bupropion.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Bupropion.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Bupropion.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Bupropion.Withdrawn
PhenelzinePhenelzine may increase the hypertensive activities of Bupropion.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Bupropion.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypertensive activities of Bupropion.Withdrawn
PhenobarbitalThe metabolism of Bupropion can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Bupropion.Withdrawn
PhenytoinThe metabolism of Bupropion can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Bupropion.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Bupropion.Approved
PioglitazoneThe metabolism of Bupropion can be decreased when combined with Pioglitazone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Bupropion.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Bupropion.Approved
PiribedilThe risk or severity of adverse effects can be increased when Piribedil is combined with Bupropion.Investigational
PirlindolePirlindole may increase the hypertensive activities of Bupropion.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Bupropion.Withdrawn
PonatinibThe metabolism of Ponatinib can be decreased when combined with Bupropion.Approved
PosaconazoleThe metabolism of Bupropion can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe serum concentration of Pramipexole can be increased when it is combined with Bupropion.Approved, Investigational
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Bupropion.Approved
PrimidoneThe metabolism of Bupropion can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Bupropion.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Bupropion.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Bupropion.Approved, Vet Approved
PromazineThe metabolism of Bupropion can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Bupropion.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Bupropion.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Bupropion.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Bupropion.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Bupropion.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Bupropion.Approved
PyrimethamineThe metabolism of Bupropion can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Bupropion can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Bupropion.Approved
QuinidineThe metabolism of Bupropion can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Bupropion.Approved
RabeprazoleThe metabolism of Bupropion can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Bupropion.Approved
RanolazineThe metabolism of Bupropion can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Bupropion.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Bupropion.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Bupropion.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Bupropion.Approved
RifabutinThe metabolism of Bupropion can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bupropion can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bupropion can be increased when combined with Rifapentine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Bupropion.Approved, Investigational
RitonavirThe serum concentration of Bupropion can be decreased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Bupropion can be decreased when combined with Rolapitant.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bupropion.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Bupropion.Approved
RosiglitazoneThe metabolism of Bupropion can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Bupropion.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Bupropion.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Bupropion.Approved
SafrazineSafrazine may increase the hypertensive activities of Bupropion.Withdrawn
SaquinavirThe metabolism of Bupropion can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Bupropion can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypertensive activities of Bupropion.Approved, Investigational, Vet Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Bupropion.Approved, Withdrawn
SertralineThe serum concentration of Bupropion can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Bupropion.Approved, Investigational
SiltuximabThe serum concentration of Bupropion can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bupropion can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Bupropion.Approved
SorafenibThe serum concentration of Bupropion can be increased when it is combined with Sorafenib.Approved, Investigational
SparteineThe metabolism of Sparteine can be decreased when combined with Bupropion.Experimental
St. John's WortThe serum concentration of Bupropion can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Bupropion can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Bupropion can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Bupropion can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Bupropion can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Bupropion resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Bupropion.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Bupropion.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Bupropion.Investigational, Withdrawn
TelaprevirThe metabolism of Bupropion can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Bupropion can be decreased when combined with Telithromycin.Approved
Tenofovir disoproxilThe metabolism of Bupropion can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Bupropion can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Bupropion.Withdrawn
TeriflunomideThe serum concentration of Bupropion can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Bupropion.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Bupropion.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Bupropion.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Bupropion.Withdrawn
ThiotepaThe serum concentration of Bupropion can be increased when it is combined with Thiotepa.Approved
TianeptineThe metabolism of Tianeptine can be decreased when combined with Bupropion.Approved
TicagrelorThe metabolism of Bupropion can be decreased when combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Bupropion can be increased when it is combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Bupropion.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Bupropion.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Bupropion.Approved, Investigational
TocilizumabThe serum concentration of Bupropion can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Bupropion can be decreased when combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypertensive activities of Bupropion.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Bupropion.Approved, Investigational
TopiroxostatThe metabolism of Bupropion can be decreased when combined with Topiroxostat.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Bupropion.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Bupropion.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Bupropion.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Bupropion.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Bupropion.Approved, Investigational
TrimethoprimThe metabolism of Bupropion can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Bupropion.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Bupropion.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Bupropion.Approved, Investigational
Valproic AcidThe metabolism of Bupropion can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Bupropion can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Bupropion can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Bupropion can be increased when it is combined with Venlafaxine.Approved
VerapamilThe metabolism of Bupropion can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Bupropion.Approved, Investigational
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Bupropion.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Bupropion.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Bupropion.Approved, Investigational
VoriconazoleThe metabolism of Bupropion can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Bupropion is combined with Vortioxetine.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Bupropion.Approved, Vet Approved
ZafirlukastThe metabolism of Bupropion can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Bupropion.Approved
ZiprasidoneThe metabolism of Bupropion can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Bupropion.Approved
ZucapsaicinThe metabolism of Bupropion can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Bupropion.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid St.John's Wort.
  • Take without regard to meals.

References

Synthesis Reference
US3819706
General References
  1. Fryer JD, Lukas RJ: Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999 Jan;288(1):88-92. [PubMed:9862757]
  2. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA: 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-13. [PubMed:16027765]
  3. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005 Aug;66(8):974-81. [PubMed:16086611]
  4. Authors unspecified: Annual report on the results of treatment in gynecological cancer. Twenty-first volume. Statements of results obtained in patients treated in 1982 to 1986, inclusive 3 and 5-year survival up to 1990. Int J Gynaecol Obstet. 1991 Sep;36 Suppl:1-315. [PubMed:1684162]
  5. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006 Oct;26(5):482-8. [PubMed:16974189]
External Links
Human Metabolome Database
HMDB01510
KEGG Drug
D07591
KEGG Compound
C06860
PubChem Compound
444
PubChem Substance
46506896
ChemSpider
431
BindingDB
50048392
ChEBI
3219
ChEMBL
CHEMBL894
Therapeutic Targets Database
DAP000052
PharmGKB
PA448687
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Bupropion
ATC Codes
A08AA62 — Bupropion and naltrexoneN06AX12 — Bupropion
AHFS Codes
  • 28:16.04.92
PDB Entries
Not Available
FDA label
Download (88.6 KB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentStress Disorders, Posttraumatic / Tobacco Use Disorders1
0RecruitingBasic ScienceCocaine Use Disorders1
1CompletedNot AvailableHealthy Volunteers7
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Bupropion / Pharmacokinetics of Isavuconazole1
1CompletedNot AvailableNicotine Dependence / Tobacco Dependence1
1CompletedBasic ScienceAlzheimer's Disease (AD) / Metabolism1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Substance-Related Disorders1
1CompletedDiagnosticDrug Interactions1
1CompletedDiagnosticHealthy Volunteers1
1CompletedDiagnosticMethamphetamine Dependence1
1CompletedDiagnosticNicotine Dependence1
1CompletedPreventionDepressive State / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHealthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedTreatmentMajor Depressive Disorder (MDD)2
1CompletedTreatmentMoods Disorders1
1CompletedTreatmentSmoking1
1CompletedTreatmentTobacco Use Disorders1
1Not Yet RecruitingOtherLeukemia, Lymphocytic, Chronic, B-Cell1
1RecruitingTreatmentTuberculosis / Tuberculosis, Pulmonary1
1TerminatedNot AvailableDepressive Disorders1
1TerminatedTreatmentCocaine-Related Disorders1
1Unknown StatusBasic ScienceSubstance-Related Disorders1
1Unknown StatusDiagnosticAmphetamine-Related Disorders1
1, 2CompletedTreatmentBipolar Disorder (BD)1
1, 2CompletedTreatmentNicotine Dependence / Smoking1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2WithdrawnSupportive CareLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAlcohol Drinking1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
2Active Not RecruitingTreatmentSmoking Lapse Behavior1
2CompletedNot AvailableBladder Cancers / Cervical Cancers / Esophageal Cancers / Head and Neck Carcinoma / Leukemias / Liver Cancer / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Renal Cancers / Tobacco Use Disorders1
2CompletedTreatmentAdolescent Methamphetamine Abuse1
2CompletedTreatmentAlcoholism / Smoking1
2CompletedTreatmentAmphetamine Dependence / Methamphetamine / Methamphetamine Dependence / Pharmacogenetics / Substance Abuse1
2CompletedTreatmentAmphetamine-Related Disorders1
2CompletedTreatmentApathy / Huntington's Disease (HD)1
2CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Nicotine Dependence1
2CompletedTreatmentBMI >30 kg/m22
2CompletedTreatmentBipolar Disorder (BD) / Depressive Disorders1
2CompletedTreatmentCessation, Smoking1
2CompletedTreatmentCessation, Smoking / Pregnancy1
2CompletedTreatmentCessation, Smoking / Schizophrenic Disorders1
2CompletedTreatmentDependence, Cocaine / Major Depressive Disorder (MDD)1
2CompletedTreatmentDepressive Disorders1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Substance Abuse1
2CompletedTreatmentMarijuana Abuse1
2CompletedTreatmentMarijuana Abuse / Substance-Related Disorders1
2CompletedTreatmentMethamphetamine1
2CompletedTreatmentMethamphetamine Dependence1
2CompletedTreatmentNicotine Dependence1
2CompletedTreatmentSchizophrenia and Disorders With Psychotic Features / Tobacco Use Disorders1
2CompletedTreatmentSchizophrenic Disorders / Tobacco Use Cessation / Tobacco Use Disorders1
2CompletedTreatmentSchizophrenic Disorders / Tobacco Use Disorders1
2CompletedTreatmentSmoking, Cigarette1
2CompletedTreatmentTobacco Use Disorders2
2Not Yet RecruitingTreatmentNicotine Dependence1
2RecruitingSupportive CareCarcinoma, Breast / Cervical Carcinoma / One to five years postmenopausal / Ovarian Carcinoma / Uterine Corpus Cancer / Vaginal Carcinoma / Vulvar Carcinoma1
2RecruitingTreatmentAlcohol Abuse1
2RecruitingTreatmentBinge Drinking1
2RecruitingTreatmentErectile Dysfunctions / Hypoactive Sexual Desire Disorder (HSDD) / Sexual Dysfunctions, Psychological1
2RecruitingTreatmentNicotine Dependence / Smoking1
2Unknown StatusTreatmentTobacco Use Cessation / Tobacco Use Disorders1
2, 3Active Not RecruitingTreatmentCessation, Smoking / Tobacco Use Disorders1
2, 3Active Not RecruitingTreatmentSmoking / Stress Disorders, Post-Traumatic1
2, 3CompletedTreatmentAdhd / Dependence, Cocaine / Opioid-Related Disorders1
2, 3CompletedTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m21
2, 3CompletedTreatmentCrohn's Disease (CD)1
2, 3CompletedTreatmentDepressive State / Suicide, Attempted1
2, 3CompletedTreatmentNicotine Dependence / Nicotine Withdrawal1
2, 3CompletedTreatmentOrgasmic Disorder1
2, 3CompletedTreatmentRestless Legs Syndrome (RLS)1
2, 3CompletedTreatmentSmoking1
2, 3Enrolling by InvitationTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m22
2, 3RecruitingTreatmentAgitation in Patients With Dementia of the Alzheimer's Type / Alzheimer's Disease (AD) / Psychomotor Agitation1
2, 3RecruitingTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m21
2, 3RecruitingTreatmentDependence, Cocaine / Substance Abuse1
2, 3TerminatedTreatmentNicotine Dependence / Smoking, Cigarette1
2, 3TerminatedTreatmentTobacco Dependence1
2, 3Unknown StatusTreatmentTobacco Use Disorders1
3Active Not RecruitingTreatmentCessation, Smoking1
3Active Not RecruitingTreatmentNicotine Dependence / Tobacco Use1
3CompletedNot AvailableUnipolar Depression1
3CompletedPreventionLung Cancers1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction (MI) / Smoking1
3CompletedTreatmentApathy in Dementia1
3CompletedTreatmentCessation, Smoking1
3CompletedTreatmentDepressive State / Major Depressive Disorder (MDD) / Unipolar Depression1
3CompletedTreatmentMajor Depressive Disorder (MDD)3
3CompletedTreatmentNicotine Dependence3
3CompletedTreatmentSmokeless Tobacco1
3CompletedTreatmentSmoking1
3CompletedTreatmentTobacco Use Disorders3
3RecruitingTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3RecruitingTreatmentBipolar I Disorder1
3RecruitingTreatmentTreatment Resistant Major Depressive Disorder1
3TerminatedPreventionLung Cancers1
3TerminatedTreatmentBMI >27 kg/m2 / BMI >30 kg/m21
3Unknown StatusTreatmentAlcohol-Related Disorders / Cessation, Smoking1
4Active Not RecruitingNot AvailableHealthy Controls / Major Depressive Disorder (MDD)1
4Active Not RecruitingTreatmentCessation, Smoking / Nicotine Addiction / Smoking, Cigarette1
4Active Not RecruitingTreatmentDepressive State1
4CompletedNot AvailableCessation, Smoking1
4CompletedNot AvailableRoux En Y Gastric Bypass1
4CompletedBasic ScienceDepressive State1
4CompletedBasic ScienceNicotine Dependence1
4CompletedHealth Services ResearchHealthy Volunteers1
4CompletedPreventionCerebrovascular Disorders / Cessation, Smoking1
4CompletedSupportive CareFriedreich's Ataxia1
4CompletedTreatmentAlcoholism / Smoking1
4CompletedTreatmentApathy / Depressive State / Sexual Dysfunctions / Side Effects1
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Cannabis Use Disorders / Nicotine Dependence1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentCancer, Breast / Major Depressive Disorder (MDD)1
4CompletedTreatmentCardiovascular Disease (CVD) / Myocardial Infarction (MI) / Smoking / Unstable Angina (UA)1
4CompletedTreatmentCessation, Smoking3
4CompletedTreatmentCessation, Smoking / Smoking / Tobacco Use Disorders1
4CompletedTreatmentDepressive State1
4CompletedTreatmentDepressive State / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4CompletedTreatmentDepressive State / Suicidal Ideation1
4CompletedTreatmentDepressive illness1
4CompletedTreatmentDysthymic Disorder1
4CompletedTreatmentDysthymic Disorder / Major Depressive Disorder (MDD)2
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentInflammatory Bowel Diseases (IBD) / Sleep Disturbances / Tiredness1
4CompletedTreatmentMajor Depressive Disorder (MDD)3
4CompletedTreatmentNicotine Dependence1
4CompletedTreatmentPregnancy Related / Tobacco Use Disorders1
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders / Tobacco-Use Disorder1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentSleep disorders and disturbances / Tobacco Use Cessation1
4CompletedTreatmentSmoking2
4CompletedTreatmentTobacco Dependence1
4CompletedTreatmentTobacco Use Disorders2
4Not Yet RecruitingTreatmentCigarette-smoking / Obese / Schizophrenic Disorders1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4Not Yet RecruitingTreatmentMajor Depressive Disorder (MDD)1
4Not Yet RecruitingTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
4RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
4RecruitingBasic ScienceType 2 Diabetes Mellitus1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingTreatmentBMI >30 kg/m2 / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
4RecruitingTreatmentDepressive Disorders1
4RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Major Depressive Disorder (MDD)1
4RecruitingTreatmentSchizophrenic Disorders / Smoking, Cigarette1
4TerminatedTreatmentBMI >30 kg/m2 / Cardiovascular Disease (CVD)1
4TerminatedTreatmentBipolar Disorder (BD) / Depressive State1
4TerminatedTreatmentDepressive State1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4TerminatedTreatmentNicotine Dependence / Sleeplessness1
4TerminatedTreatmentTobacco Use Disorders1
4Unknown StatusTreatmentAlcoholism / Depressive State / Suicidal Behaviour1
4Unknown StatusTreatmentBipolar Disorder (BD)1
4Unknown StatusTreatmentDepressive State2
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD) / Nicotine Dependence1
4WithdrawnTreatmentDepressive Disorder Not Otherwise Specified (NOS) / Dysthymic Disorder / Major Depressive Disorder (MDD)1
Not AvailableActive Not RecruitingNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableActive Not RecruitingTreatmentHomelessness / Tobacco Use Disorders1
Not AvailableActive Not RecruitingTreatmentSmoking1
Not AvailableCompletedNot AvailableBladder Cancers / Cervical Cancers / Esophageal Cancers / Head and Neck Carcinoma / Leukemias / Liver Cancer / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Renal Cancers / Tobacco Use Disorders1
Not AvailableCompletedNot AvailableCancer and Tobacco Abuse1
Not AvailableCompletedNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableCompletedBasic ScienceDepressive State1
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depressive State / Psychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedPreventionCancer Survivors / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentAlcohol Drinking / Attention Deficit Disorder (ADD) / Cessation, Smoking / Depressive State1
Not AvailableCompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Substance Use Disorder (SUD)1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentCocaine-Related Disorders1
Not AvailableCompletedTreatmentGambling / Pathological Gambling1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentHomeless Persons / Smoking1
Not AvailableCompletedTreatmentNicotine Dependence1
Not AvailableCompletedTreatmentNicotine Dependence / Tobacco Use Disorders1
Not AvailableCompletedTreatmentPTSD / Smoking1
Not AvailableCompletedTreatmentPeriodontitis1
Not AvailableCompletedTreatmentTobacco Use Disorders1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableEnrolling by InvitationNot AvailableCessation, Smoking1
Not AvailableNot Yet RecruitingTreatmentNicotine Dependence / Smokeless Tobacco1
Not AvailableRecruitingNot AvailableDepressive State1
Not AvailableRecruitingNot AvailableDepressive State / Suicidal Ideation1
Not AvailableRecruitingPreventionCurrent Smokers / Head and Neck Squamous Cell Carcinoma (HNSCC) / Hypopharyngeal Squamous Cell Carcinoma / Laryngeal Squamous Cell Carcinoma / Nasopharyngeal Carcinoma / Oral Cavity Squamous Cell Carcinoma / Oropharyngeal Squamous Cell Carcinoma1
Not AvailableRecruitingScreeningAcute Coronary Syndromes (ACS) / Depressive Symptoms1
Not AvailableRecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Nicotine Dependence1
Not AvailableRecruitingTreatmentAlcohol Drinking / Cessation, Smoking1
Not AvailableRecruitingTreatmentAntidepressant Drug Adverse Reaction / Depressive State1
Not AvailableRecruitingTreatmentMarijuana Abuse / Smoking, Cigarette1
Not AvailableTerminatedNot AvailableSmoking1
Not AvailableUnknown StatusNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusDiagnosticTobacco Use Disorders1
Not AvailableUnknown StatusTreatmentCessation, Smoking1
Not AvailableUnknown StatusTreatmentCessation, Smoking / Smoking1
Not AvailableUnknown StatusTreatmentMethamphetamine Use Disorder1
Not AvailableUnknown StatusTreatmentNicotine Dependence / Nicotine Use Disorder1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral174 mg/1
Tablet, extended releaseOral348 mg/1
Tablet, extended releaseOral522 mg/1
Kit
Tablet, extended releaseOral150 mg/1
TabletOcclusive dressing technique150 mg/1
TabletOral100 mg/1
TabletOral75 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, film coatedOcclusive dressing technique75 mg/1
Tablet, film coated, extended releaseOcclusive dressing technique150 mg/1
TabletOral150 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral150 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Tablet, film coated, extended releaseOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral450 mg/1
Tablet, extended releaseOral100 mg
Tablet, film coatedOral75 mg/1
Tablet, extended releaseOral150 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral200 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral300 mg
Prices
Unit descriptionCostUnit
Aplenzin er 522 mg tablet16.74USD tablet
Bupropion hydrochloride powder10.2USD g
Wellbutrin XL 300 mg 24 Hour tablet9.03USD tablet
Wellbutrin xl 300 mg tablet8.68USD tablet
Wellbutrin SR 200 mg 12 Hour tablet7.57USD tablet
Aplenzin er 348 mg tablet7.36USD tablet
Wellbutrin sr 200 mg tablet7.27USD tablet
Wellbutrin XL 150 mg 24 Hour tablet6.84USD tablet
Wellbutrin xl 150 mg tablet6.58USD tablet
Aplenzin er 174 mg tablet5.58USD tablet
BuPROPion HCl 300 mg 24 Hour tablet4.96USD tablet
Wellbutrin SR 150 mg 12 Hour tablet4.07USD tablet
BuPROPion HCl 200 mg 12 Hour tablet3.99USD tablet
Wellbutrin sr 150 mg tablet3.92USD tablet
Zyban 150 mg 12 Hour tablet3.88USD tablet
Wellbutrin SR 100 mg 12 Hour tablet3.8USD tablet
Zyban sr 150 mg tablet3.73USD tablet
Wellbutrin sr 100 mg tablet3.66USD tablet
Wellbutrin 100 mg tablet3.62USD tablet
BuPROPion HCl 150 mg 12 Hour tablet3.02USD tablet
Wellbutrin 75 mg tablet2.71USD tablet
BuPROPion HCl (Smoking Deter) 150 mg 12 Hour tablet2.01USD tablet
Wellbutrin Xl 300 mg Extended-Release Tablet1.12USD tablet
Bupropion hcl 100 mg tablet0.98USD tablet
Wellbutrin Sr 150 mg Sustained-Release Tablet0.96USD tablet
Bupropion hcl 75 mg tablet0.74USD tablet
Wellbutrin Xl 150 mg Extended-Release Tablet0.56USD tablet
Pms-Bupropion Sr 150 mg Sustained-Release Tablet0.53USD tablet
Ratio-Bupropion Sr 150 mg Sustained-Release Tablet0.53USD tablet
Sandoz Bupropion Sr 150 mg Sustained-Release Tablet0.53USD tablet
Sandoz Bupropion Sr 100 mg Sustained-Release Tablet0.35USD tablet
Ratio-Bupropion Sr 100 mg Sustained-Release Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5358970No1993-08-122013-08-12Us
CA2524300No2008-10-282023-08-08Canada
CA2168364No2001-09-182014-07-29Canada
US7569610No2006-06-272026-06-27Us
US7662407No2006-06-272026-06-27Us
US7241805No2006-06-272026-06-27Us
US7649019No2006-06-272026-06-27Us
US7645802No2006-06-272026-06-27Us
US7671094No2006-06-272026-06-27Us
US7572935No2006-06-272026-06-27Us
US7585897No2006-06-272026-06-27Us
US6096341No1998-10-302018-10-30Us
US7674479No2007-06-252027-06-25Us
US8722085No2007-11-082027-11-08Us
US8318788No2007-11-082027-11-08Us
US7462626No2004-07-202024-07-20Us
US8815889No2004-07-202024-07-20Us
US9107837No2007-06-042027-06-04Us
US9125868No2007-11-082027-11-08Us
US8916195No2010-02-022030-02-02Us
US9248123No2012-01-132032-01-13Us
US8088786No2009-02-032029-02-03Us
US7375111No2005-03-262025-03-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)233-234 °CNot Available
water solubility312 mg/mlNot Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0693 mg/mLALOGPS
logP3.28ALOGPS
logP3.27ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)18.29ChemAxon
pKa (Strongest Basic)8.22ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.1 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity67.7 m3·mol-1ChemAxon
Polarizability25.93 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.975
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.733
P-glycoprotein inhibitor INon-inhibitor0.8738
P-glycoprotein inhibitor IINon-inhibitor0.9343
Renal organic cation transporterNon-inhibitor0.8814
CYP450 2C9 substrateNon-substrate0.785
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.574
CYP450 1A2 substrateNon-inhibitor0.7499
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorNon-inhibitor0.7743
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5141
Ames testNon AMES toxic0.9233
CarcinogenicityNon-carcinogens0.5609
BiodegradationNot ready biodegradable0.9892
Rat acute toxicity2.4363 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9684
hERG inhibition (predictor II)Non-inhibitor0.8886
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-c10af1c8e3619fe0bffc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0490000000-55448af4d9a8ce866a88
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-2883ba18321a8b8228a1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0159-0900000000-7d6cad849706146ddab3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0159-0900000000-0fca8999746b69ee4fc1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-b64f8d2b50bede574f63
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-2edefa63d5f6f1b08db7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0490000000-b8ea1de058a84547700d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0910000000-6f471b9150fb1b7f6fcc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0159-0900000000-cc966137ee3283828af7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0900000000-7f86f38f740aa41b244b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e7f2cfdbabbd35a9b643
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-4daf0e10db1e5f2750bf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-f77a450be176593153d2
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00m0-0910000000-d2eb7265b058766459c9
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0910000000-fa2592b7296c7561333c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0900000000-4d831e97d7e7dfff141b

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylpropanes / Benzoyl derivatives / Aryl alkyl ketones / Chlorobenzenes / Aryl chlorides / Alpha-amino ketones / Dialkylamines / Organopnictogen compounds / Organochlorides / Organic oxides
show 1 more
Substituents
Alkyl-phenylketone / Phenylpropane / Benzoyl / Aryl alkyl ketone / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid
show 12 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary amino compound, monochlorobenzenes, propanone, aromatic ketone (CHEBI:3219)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Miller DK, Sumithran SP, Dwoskin LP: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exp Ther. 2002 Sep;302(3):1113-22. [PubMed:12183670]
  2. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S: Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002 Aug;163(1):102-5. Epub 2002 Jul 13. [PubMed:12185406]
  3. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, Seibyl JP, Innis RB: Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003 Feb;28(2):413-20. Epub 2002 Jul 19. [PubMed:12589396]
  4. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B: In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003 Oct 15;54(8):800-5. [PubMed:14550679]
  5. Szabo Z, Argyelan M, Kanyo B, Pavics L, Janka Z: [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]. Neuropsychopharmacol Hung. 2004 Jun;6(2):79-81. [PubMed:15787205]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  8. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S: A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166. [PubMed:15361919]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Bondarev ML, Bondareva TS, Young R, Glennon RA: Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003 Aug 1;474(1):85-93. [PubMed:12909199]
  2. Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S: A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166. [PubMed:15361919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA3
Uniprot ID
P32297
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-3
Molecular Weight
57479.54 Da
References
  1. Fryer JD, Lukas RJ: Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999 Jan;288(1):88-92. [PubMed:9862757]
  2. Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000 Oct;295(1):321-7. [PubMed:10991997]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013]
  4. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000 Oct;28(10):1176-83. [PubMed:10997936]
  5. Jefferson JW, Pradko JF, Muir KT: Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther. 2005 Nov;27(11):1685-95. [PubMed:16368442]
  6. Foley KF, DeSanty KP, Kast RE: Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006 Sep;6(9):1249-65. [PubMed:17009913]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Foley KF, DeSanty KP, Kast RE: Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006 Sep;6(9):1249-65. [PubMed:17009913]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:53